EP1675828A1 - PROCESS FOR THE PREPARATION OF (1alpha, 5alpha, 6alpha)-6-AMINOME THYL-3-BENZYL-3-AZBICYCLO [3.1.0] HEXANE - Google Patents
PROCESS FOR THE PREPARATION OF (1alpha, 5alpha, 6alpha)-6-AMINOME THYL-3-BENZYL-3-AZBICYCLO [3.1.0] HEXANEInfo
- Publication number
- EP1675828A1 EP1675828A1 EP04769411A EP04769411A EP1675828A1 EP 1675828 A1 EP1675828 A1 EP 1675828A1 EP 04769411 A EP04769411 A EP 04769411A EP 04769411 A EP04769411 A EP 04769411A EP 1675828 A1 EP1675828 A1 EP 1675828A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- reaction
- compound
- hexane
- carried out
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Definitions
- the present invention relates to a new and industrially advantageous process for the preparation of (l ⁇ , 5 ⁇ , 6 ⁇ )-6-aminomethyl-3-benzyl-3-azabicyclo[3.1.0]hexane of Formula I,
- This compound is a key intermediate for the synthesis of azabicyclo quinolone derivatives as antimicrobials and for the synthesis of various azabicyclo[3.1.0]hexane derivatives as muscarinic receptor antagonists.
- azabicyclo quinolone derivatives are known in U.S. Patent Nos. 5,164,402; 5,391,763; 5,229,396; 5,266,569 and European Patent Application No. 0413455 A2.
- the azabicyclo quinolone derivatives are useful in the broad spectrum treatment of bacterial infections. They are particularly active against sensitive and resistant strains of gram-positive pathogens like methicillin resistant staphylococcus aureus (MRSA), methicillin resistant staphylococcus epidermidis (MRSE), quinolone resistant staphylococcus aureus (QRSA) and Vancomycin resistant enterococci (VRSE).
- MRSA methicillin resistant staphylococcus aureus
- MRSE methicillin resistant staphylococcus epidermidis
- QRSA quinolone resistant staphylococcus aureus
- VRSE Vancomycin resistant enterococci
- WO 2004/052857 and WO 04/004629 disclose 3, 6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists.
- WO 04/005252 discloses azabicyclo derivatives as musacrinic receptor antagonists.
- WO 04/014853, WO 04/067510 and WO 04/014363 disclose derivatives of 3, 6-disubstituted azabicyclohexane useful as muscarinic receptor antagonists.
- WO 2004/056810 discloses xan bine derivatives as muscarinic receptor antagonists.
- WO 2004/056811 discloses flaxavate derivatives as muscarinic receptor antagonists.
- WO 2004/056767 discloses 1-substituted- 3-pyrrolidine derivatives as muscarinic receptor antagonists.
- WO 2004/018422 disclose fluoro and sulphonylamino containing 3, 6-disubstituted azabicyclo[3.1.0] hexane derivatives as muscarinic receptor antagonists.
- the processes require the use of oxalyl chloride, which is a corrosive, toxic, moisture-sensitive reagent and hence difficult to handle on commercial scale.
- the processes require the use of lithium aluminum hydride, which is a very corrosive, air sensitive, hygroscopic and flammable reagent, which thus pose a handling problem.
- the reaction conditions involve the use of tetrahydrofuran, which is unsafe and can involve the risk of explosion and fire due to peroxide formation. Tetrahydrofuran and lithium aluminum hydride are expensive reagents and add significant factor in the overall cost of preparation of final product. Removal of dimethylsulhoxide is difficult as it is high temperature evaporating solvent.
- Formula V in the presence of a catalyst and an organic base in an organic solvent at a temperature ranging from 0-5°C.
- the reaction can be carried out in the presence of a hypernucleophilic catalyst, such as, for example, N,N-dimethyl amino pyridine.
- Trie organic base can be selected from for example triethylamine and pyridine.
- the organic solvent can be selected from for example, dichloromethane, dichloroethane, chloroform and ethyl acetate.
- the compound of Formula V is further reacted with aqueous ammonia solution to give a compound of Formula I in an organic solvent at a temperature ranging from 75-80°C.
- the organic solvent can be selected from for example metlranol, ethanol, n-propanol and isopropyl alcohol in acetonitrile.
- liquid ammonia solution can also be used in place of aqueous ammonia solution.
- reaction mixture was diluted with dichloromethane and washed with saturated aqueous solution of sodium bicarbonate.
- the organic layer was separated, washed with water and brine solution, dried over anhydrous sodium sulphate and concentrated under reduced pressure to yield the title compound with a yield of 74%.
- Step b Preparation of (l ⁇ ,5 ⁇ ,6 ⁇ )-6-aminomethyl-3-azabicyclo[3.1.0]hexane (Formula I) To a solution of a compound obtained from step a above (1 g) in methanol was added aqueous ammonia solution (25% w ⁇ v, 10 ml). The reaction mixture was placed in autoclave and sealed tightly and heated at 75-80°C for approx. 12 hours followed by cooling it to room temperature. The solvent was removed under vacuum and the residue was diluted with water. The pH of the solution was adjusted to 1-2 with 2N hydrochloric acid followed by washing with toluene. The pH of the aqueous layer was adjusted to 13- 14 with 2N sodium hydroxide.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1169DE2003 | 2003-09-18 | ||
PCT/IB2004/003037 WO2005026122A1 (en) | 2003-09-18 | 2004-09-17 | PROCESS FOR THE PREPARATION OF (1α, 5α, 6α)-6-AMINOMETHYL-3-BENZYL-3-AZBICYCLO[3.1.0]HEXANE |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1675828A1 true EP1675828A1 (en) | 2006-07-05 |
Family
ID=34308047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04769411A Withdrawn EP1675828A1 (en) | 2003-09-18 | 2004-09-17 | PROCESS FOR THE PREPARATION OF (1alpha, 5alpha, 6alpha)-6-AMINOME THYL-3-BENZYL-3-AZBICYCLO [3.1.0] HEXANE |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1675828A1 (en) |
WO (1) | WO2005026122A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007039884A1 (en) | 2005-10-05 | 2007-04-12 | Ranbaxy Laboratories Limited | 3 -azabicyclooctane derivatives as muscarinic receptor antagonists |
EP1968980A1 (en) | 2005-12-30 | 2008-09-17 | Ranbaxy Laboratories, Ltd. | Muscarinic receptor antagonists |
WO2009068876A1 (en) * | 2007-11-30 | 2009-06-04 | Summit Corporation Plc | Compositions for the treatment of skin disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164402A (en) * | 1989-08-16 | 1992-11-17 | Pfizer Inc | Azabicyclo quinolone and naphthyridinone carboxylic acids |
-
2004
- 2004-09-17 WO PCT/IB2004/003037 patent/WO2005026122A1/en not_active Application Discontinuation
- 2004-09-17 EP EP04769411A patent/EP1675828A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2005026122A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005026122A1 (en) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2545048B1 (en) | Raltegravir salts and crystalline forms thereof | |
WO2016180275A1 (en) | Ahu-377 intermediates and method for preparing ahu-377 and ahu-377 intermediates | |
CN108440330A (en) | A kind of preparation method of Doxycycline Hyclate | |
CN112574190B (en) | Method for synthesizing chlorantraniliprole | |
US20040014983A1 (en) | Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide | |
EP1675828A1 (en) | PROCESS FOR THE PREPARATION OF (1alpha, 5alpha, 6alpha)-6-AMINOME THYL-3-BENZYL-3-AZBICYCLO [3.1.0] HEXANE | |
WO2009157525A1 (en) | Method for producing 3-methyl-2-thiophenecarboxylic acid | |
CN108558785B (en) | 5-aryl-2-arylseleno-1, 3-oxazole compound and preparation method thereof | |
CN107540575B (en) | Preparation method of sitagliptin intermediate | |
WO2012060232A1 (en) | 5-trifluoromethyl-4-nitro-2-isoxazoline compounds and preparing process therefor | |
EP1670759A1 (en) | PROCESS FOR THE PREPARATION OF (1a, 5a, 6a)-6-AMINOME THYL-3-BENZYL-3-AZABICYCLO 3.1.0 HEXANE | |
US20230382887A1 (en) | Process for the preparation of chlorantraniliprole | |
CN107602454B (en) | Sulfonamide compound and preparation method and application thereof | |
JP2006528978A (en) | Method for the synthesis of β-lactamase inhibitor intermediates | |
WO2010000197A1 (en) | A method for preparing 5h-cyano-imido stilbene | |
JP4220619B2 (en) | Method for producing indene carbonate | |
JP2008137898A (en) | Method for producing 4-methylthio-3-butenylisothiocyanate, its synthetic intermediate, and antimicrobial composition containing the same | |
WO2007013323A1 (en) | 4,5-di(5-tetrazolyl)-[1,2,3]triazole compound and process for producing the same | |
JPH06340623A (en) | Production of benzylsuccinic acid derivative and intermediate for its synthesis | |
JPH0987288A (en) | Purification method for 1,3-bis(3-aminopropyl)-1,1,3,3-tetraorganodisiloxane | |
CN116813517A (en) | Vinyl sulfonyl fluoride compound, intermediate thereof, preparation method and application | |
CN109970681A (en) | A kind of synthetic method of Repaglinide | |
KR100310936B1 (en) | A process for preparing N-(4-methylbenzenesulfonyl)-N'-(3-azabicyclo[3,3,0]octane)urea | |
JP4294747B2 (en) | Hydroxypiperidine derivative and method for producing the same | |
CN116730939A (en) | Preparation method of famoxadone characteristic impurities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060418 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RAX | Requested extension states of the european patent have changed |
Extension state: MK Payment date: 20060418 Extension state: LV Payment date: 20060418 Extension state: LT Payment date: 20060418 Extension state: AL Payment date: 20060418 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070403 |